Key result
Visfatin worsens pressure-overload cardiac remodeling and LVEF reduction via macrophage-driven oxidative stress in mice.
Why the study?
Previous studies reported that visfatin regulates macrophage polarisation, which participates in cardiac remodelling. Whether visfatin participates in transverse aortic constriction-induced cardiac remodelling by regulating macrophage polarisation was unknown.
Does exogenous visfatin aggravate transverse aortic constriction-induced cardiac remodelling and dysfunction by regulating macrophage polarisation and oxidative stress in mice?
Does exogenous visfatin aggravate transverse aortic constriction-induced cardiac remodelling and dysfunction by regulating macrophage polarisation and oxidative stress in mice?
This preclinical study demonstrates that visfatin exacerbates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice via macrophage-mediated oxidative stress, identifying visfatin as a potential therapeutic target for pathological cardiac remodelling.
Answers are grounded in this paper and cite their sources.
Visfatin-macrophage axis may modulate pressure-overload remodeling; leaves open whether inhibition improves human HF outcomes.
Previous studies have reported that visfatin can regulate macrophage polarisation, which has been demonstrated to participate in cardiac remodelling. The aims of this study were to investigate whether visfatin participates in transverse aortic constriction (TAC)-induced cardiac remodelling by regulating macrophage polarisation. First, TAC surgery and angiotensin II (Ang II) infusion were used to establish a mouse cardiac remodelling model, visfatin expression was measured, and the results showed that TAC surgery or Ang II infusion increased visfatin expression in the serum and heart in mice, and phenylephrine or hydrogen peroxide promoted the release of visfatin from macrophages in vitro. All these effects were dose-dependently reduced by superoxide dismutase. Second, visfatin was administered to TAC mice to observe the effects of visfatin on cardiac remodelling. We found that visfatin increased the cross-sectional area of cardiomyocytes, aggravated cardiac fibrosis, exacerbated cardiac dysfunction, further regulated macrophage polarisation and aggravated oxidative stress in TAC mice. Finally, macrophages were depleted in TAC mice to investigate whether macrophages mediate the regulatory effect of visfatin on cardiac remodelling, and the results showed that the aggravating effects of visfatin on oxidative stress and cardiac remodelling were abrogated. Our study suggests that visfatin enhances cardiac remodelling by promoting macrophage polarisation and enhancing oxidative stress. Visfatin may be a potential target for the prevention and treatment of clinical cardiac remodelling.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2023) studied Transverse aortic constriction (TAC)-induced or Angiotensin II-induced cardiac remodelling in mice. Exogenous visfatin administration (with or without macrophage depletion via clodronate liposomes or N-acetyl-cysteine) vs. PBS or control liposomes in sham-operated or TAC-operated mice was evaluated on Cardiac remodelling (cardiomyocyte cross-sectional area, left ventricular fibrosis, cardiac hypertrophy markers, and echocardiographic LVEF/FS) and macrophage-mediated oxidative stress at 28 days (p=<0.05). Visfatin (/kg/day) aggravated TAC-induced cardiomyocyte hypertrophy, cardiac fibrosis, LVEF reduction, and oxidative stress in mice, which macrophage depletion reversed.
Synapse has enriched 10 related papers. Consider them for comparative context: